1. | Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators.Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC.PMID: 31765604 Free PMC article. Clinical Trial. |
2. | Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II.Hung CC, Cheng CC, Huang WC, Lin KC, Kuo FY, Kuo SH, Yang TH, Liang HL, Mar GY.Acta Cardiol Sin. 2020 Nov;36(6):583-587. doi: 10.6515/ACS.202011_36(6).20200507A.PMID: 33235413 Free PMC article. Review. |
3. | Managing Pulmonary Hypertension in Times of COVID-19.Wang YC, Huang WC, Cheng CC, Hung CC, Kuo FY, Mar GY.Acta Cardiol Sin. 2020 Jul;36(4):394-395. doi: 10.6515/ACS.202007_36(4).20200619C.PMID: 32675934 Free PMC article. No abstract available. |
4. | MMP-10 from M1 macrophages promotes pulmonary vascular remodeling and pulmonary arterial hypertension.Chi PL, Cheng CC, Hung CC, Wang MT, Liu HY, Ke MW, Shen MC, Lin KC, Kuo SH, Hsieh PP, Wann SR, Huang WC.Int J Biol Sci. 2022 Jan 1;18(1):331-348. doi: 10.7150/ijbs.66472. eCollection 2022.PMID: 34975336 Free PMC article. |
5. | 2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension.Huang WC, Hsu CH, Sung SH, Ho WJ, Chu CY, Chang CP, Chiu YW, Wu CH, Chang WT, Lin L, Lin SL, Cheng CC, Wu YJ, Wu SH, Hsieh TY, Hsu HH, Fu M, Dai ZK, Kuo PH, Hwang JJ, Cheng SM; TSOC pulmonary hypertension committee.J Formos Med Assoc. 2019 Dec;118(12):1584-1609. doi: 10.1016/j.jfma.2018.12.009. Epub 2019 Mar 26.PMID: 30926248 Free article. |